KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) EBT (2016 - 2025)

Pfizer (PFE) has disclosed EBT for 17 consecutive years, with -$1.6 billion as the latest value for Q4 2025.

  • Quarterly EBT changed N/A to -$1.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.5 billion through Dec 2025, changed N/A year-over-year, with the annual reading at $7.5 billion for FY2025, 6.27% down from the prior year.
  • EBT for Q4 2025 was -$1.6 billion at Pfizer, down from $3.3 billion in the prior quarter.
  • The five-year high for EBT was $11.4 billion in Q3 2022, with the low at -$4.1 billion in Q4 2023.
  • Average EBT over 5 years is $3.9 billion, with a median of $3.4 billion recorded in 2024.
  • The sharpest move saw EBT plummeted 137.24% in 2023, then skyrocketed 3055.34% in 2025.
  • Over 5 years, EBT stood at $7.8 billion in 2021, then increased by 14.76% to $9.0 billion in 2022, then plummeted by 145.87% to -$4.1 billion in 2023, then soared by 214.19% to $4.7 billion in 2024, then plummeted by 134.83% to -$1.6 billion in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$1.6 billion, $3.3 billion, and $3.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.